x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Address of principal executive offices) (Zip Code) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-36534 IRADIMED CORPORATION (Exact Name of Registrant As Specified In Its Char ...

Financial Data and Key Metrics Changes - The company reported fourth quarter 2018 revenue of $8.3 million, a 24.4% increase compared to the same quarter last year, and a 9.5% increase sequentially [7][21] - GAAP net income for the fourth quarter was $0.14 per diluted share, compared to $0.02 for the same quarter last year, while non-GAAP income was $0.16 per diluted share, up from $0.10 [25] - For the full year 2018, revenue increased by 31.9%, with approximately 65% of growth from patient monitoring systems and 12.4% from IV pumps [7] Business Line Data and Key Metrics Changes - Revenue from devices in Q4 2018 was $5.9 million, up from $4.7 million in Q4 2017, with $2.1 million from MRI compatible patient vital signs monitors, compared to $0.9 million in the prior year [21] - Revenue from disposables and services was $2 million in Q4 2018, compared to $1.7 million in Q4 2017 [21] - The average selling price (ASP) of IV pumps was approximately $35,000 in Q4 2018, up from $33,900 in Q4 2017, while the ASP for patient vital signs monitoring systems was approximately $34,900, compared to $29,400 in the previous year [22][23] Market Data and Key Metrics Changes - Domestic revenue for Q4 2018 was $6.7 million, compared to $5.3 million in Q4 2017, while international sales were $1.6 million, up from $1.4 million [21] - The international team achieved record bookings, particularly strong in patient monitoring orders, indicating market recognition of the product's advantages [14] Company Strategy and Development Direction - The company aims to achieve a $100 million revenue goal over five years, with expectations for growth in both the pump and monitor businesses [34] - The strategy includes bundling the new patient monitor with IV pumps to differentiate the product offering and enhance workflow for hospitals [15] - The company plans to expand its sales team to penetrate the market more effectively, adding new sales managers and clinical applications specialists [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, despite a temporary setback due to CE Mark issues affecting European sales [11][36] - The company expects revenue for 2019 to be between $38.5 million and $39.5 million, with GAAP earnings per share guidance of $0.60 to $0.64 [11] Other Important Information - The company is on track to release a next-generation IV pump in early 2021 and a magnetic detection device in late 2019 [10] - The effective tax rate for Q4 2018 was 9%, significantly lower than the previous year's rate of 82.2%, primarily due to tax reforms [25] Q&A Session Summary Question: Can you provide more details on the growth expectations for the pump and monitor? - Management indicated strong growth in both product lines, with expectations for continued improvement in sales performance [32][34] Question: Why does the outlook appear back-end loaded? - The back-end loading is primarily due to the impact of the CE Mark issue, which is expected to resolve in Q2 [36] Question: What is the outlook for gross margins? - Management expects some efficiencies to improve gross margins as production increases [37] Question: How is competition reacting in terms of pricing? - The company is tracking to expected average selling prices, with no significant changes in competitor pricing noted [39] Question: What features will the next-generation pump have? - The new pump will feature an interactive display designed to be more user-friendly, addressing usability issues with current models [49] Question: What is the revenue potential for the magnetic detection device? - The addressable market for the magnetic detection device is significant, with potential sales to all MRI facilities worldwide [55][57]